CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Cullinan Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$13.98+1.05 (+8.12%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Cullinan Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	88	83	98	156	60	168	–
Short-Term Investments	290	316	369	311	231	42	–
Cash & Short-Term Investments	378	399	467	467	290	210	–
Prepaid Expenses & Other	8.86	16	13	7.18	6.10	2.07	–
Other Current Assets	–	–	3.90	–	–	–	–
Total Current Assets	387	415	480	474	297	212	–
Property, Plant & Equipment	0.42	0.68	0.99	1.17	0.08	0.13	–
Gross Property, Plant & Equipment	1.39	1.34	1.34	1.31	0.31	0.31	–
Accumulated Depreciation	-0.97	-0.66	-0.35	-0.14	-0.23	-0.18	–
Long-Term Investments	58	204	0	81	140	0	–
Operating Lease Right-of-Use Assets	2.63	1.67	2.54	4.13	0	–	–
Other Long-Term Assets	0.30	0.37	0.46	0.46	0.15	2.30	–
Total Assets	448	622	484	561	437	215	–
Accounts Payable	0.84	1.68	2.49	2.66	3.17	9.68	–
Accrued Expenses	36	28	24	14	8.58	4.64	–
Current Portion of Leases	0.78	1.30	1.44	1.42	0.51	–	–
Current Income Taxes Payable	–	–	0	4.28	0	–	–
Other Current Liabilities	1.00	1.44	0.91	1.96	0.97	–	–
Total Current Liabilities	38	31	28	22	12	14	–
Long-Term Leases	1.90	0.85	2.15	3.59	0.87	–	–
Operating Lease Liabilities	2.68	2.15	3.59	5.01	1.38	–	–
Total Liabilities	40	31	30	26	12	14	–
Preferred Stock	0	0	0	0	–	–	–
Common Stock	0.01	0.01	0.00	0.01	0.00	0.00	0.00
Additional Paid-In Capital	996	959	655	585	585	292	139
Retained Earnings	-588	-368	-201	-48	-159	-93	-42
Comprehensive Income & Other	1.02	-0.13	-0.13	-2.60	-0.84	0.00	0.00
Shareholders' Equity	409	590	454	535	425	199	97
Noncontrolling Interest	0	0	0.19	0	0.40	1.30	0.86
Total Equity	409	590	454	535	425	200	98
Total Liabilities & Equity	448	622	484	561	437	215	–
Shares Outstanding(shares)	60	59	43	46	44	30	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -44.0%

Financial strength

Current ratio: 8.42
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 193.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –